AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) saw unusually-strong trading volume on Friday . Approximately 2,395,779 shares traded hands during mid-day trading, an increase of 102% from the previous session’s volume of 1,187,550 shares.The stock last traded at $3.30 and had previously closed at $3.25.

A number of equities research analysts have recently commented on ACRX shares. Stifel Nicolaus raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Royal Bank Of Canada set a $6.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, August 4th. Finally, Piper Jaffray Companies set a $3.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $7.50.

The stock has a 50-day moving average of $3.17 and a 200-day moving average of $2.81. The stock’s market capitalization is $149.75 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. The firm had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. AcelRx Pharmaceuticals had a negative net margin of 319.19% and a negative return on equity of 478.66%. Equities analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) EPS for the current fiscal year.

In other news, CEO Vincent J. Angotti bought 15,000 shares of AcelRx Pharmaceuticals stock in a transaction on Thursday, August 24th. The stock was purchased at an average cost of $3.00 per share, with a total value of $45,000.00. Following the purchase, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at approximately $45,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Pamela P. Palmer bought 10,000 shares of AcelRx Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $29,500.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 30,000 shares of company stock valued at $89,600 over the last three months. 28.10% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new position in AcelRx Pharmaceuticals during the 2nd quarter valued at about $530,000. WealthTrust Axiom LLC raised its position in shares of AcelRx Pharmaceuticals by 50.0% during the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after buying an additional 70,000 shares in the last quarter. LMR Partners LLP bought a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter worth about $319,000. Virtu KCG Holdings LLC raised its position in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares in the last quarter. 23.32% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/08/acelrx-pharmaceuticals-inc-acrx-sees-large-volume-increase-4.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.